BioCentury
ARTICLE | Company News

Nimbus Therapeutics, Roche, Genentech deal

October 26, 2015 7:00 AM UTC

Nimbus granted Roche’s Genentech unit exclusive, worldwide rights to develop and commercialize small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4). The partners declined to name specific programs or indications the partners will study, but Genentech said that its “primary interest is in immunological disorders.” ...